The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global Overactive Bladder Drug Market Research Report 2025
Synopsis
The global Overactive Bladder Drug market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for Overactive Bladder Drug, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Overactive Bladder Drug.
Report Scope
The Overactive Bladder Drug market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Overactive Bladder Drug market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Overactive Bladder Drug manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Astellas Pharma, Inc. (Japan)
Pfizer, Inc. (US)
Teva Pharmaceutical Industries Limited (Israel)
Allergan, Plc (Ireland)
Medtronic plc (Ireland)
Mylan N.V. (US)
Endo International plc (Ireland)
Hisamitsu Pharmaceutical Co., Inc. (Japan)
Sanofi (France)
Apotex, Inc. (Canada)
Cogentix Medical, Inc. (US)
Aurobindo Pharma Limited (India)
Segment by Type
Anticholinergics
Solifenacin
Oxybutynin
Darifenacin
Fesoterodine
Tolterodine
Trospium
Others
Segment by Application
Idiopathic Bladder Overactivity
Neurogenic Bladder Overactivity
Consumption by Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Overactive Bladder Drug manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Overactive Bladder Drug in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.
The global Overactive Bladder Drug market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for Overactive Bladder Drug, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Overactive Bladder Drug.
Report Scope
The Overactive Bladder Drug market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Overactive Bladder Drug market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Overactive Bladder Drug manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Astellas Pharma, Inc. (Japan)
Pfizer, Inc. (US)
Teva Pharmaceutical Industries Limited (Israel)
Allergan, Plc (Ireland)
Medtronic plc (Ireland)
Mylan N.V. (US)
Endo International plc (Ireland)
Hisamitsu Pharmaceutical Co., Inc. (Japan)
Sanofi (France)
Apotex, Inc. (Canada)
Cogentix Medical, Inc. (US)
Aurobindo Pharma Limited (India)
Segment by Type
Anticholinergics
Solifenacin
Oxybutynin
Darifenacin
Fesoterodine
Tolterodine
Trospium
Others
Segment by Application
Idiopathic Bladder Overactivity
Neurogenic Bladder Overactivity
Consumption by Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Overactive Bladder Drug manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Overactive Bladder Drug in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.
Index1 Overactive Bladder Drug Market Overview
1.1 Product Overview and Scope of Overactive Bladder Drug
1.2 Overactive Bladder Drug Segment by Type
1.2.1 Global Overactive Bladder Drug Market Value Comparison by Type (2024-2030)
1.2.2 Anticholinergics
1.2.3 Solifenacin
1.2.4 Oxybutynin
1.2.5 Darifenacin
1.2.6 Fesoterodine
1.2.7 Tolterodine
1.2.8 Trospium
1.2.9 Others
1.3 Overactive Bladder Drug Segment by Application
1.3.1 Global Overactive Bladder Drug Market Value by Application: (2024-2030)
1.3.2 Idiopathic Bladder Overactivity
1.3.3 Neurogenic Bladder Overactivity
1.4 Global Overactive Bladder Drug Market Size Estimates and Forecasts
1.4.1 Global Overactive Bladder Drug Revenue 2019-2030
1.4.2 Global Overactive Bladder Drug Sales 2019-2030
1.4.3 Global Overactive Bladder Drug Market Average Price (2019-2030)
1.5 Assumptions and Limitations
2 Overactive Bladder Drug Market Competition by Manufacturers
2.1 Global Overactive Bladder Drug Sales Market Share by Manufacturers (2019-2024)
2.2 Global Overactive Bladder Drug Revenue Market Share by Manufacturers (2019-2024)
2.3 Global Overactive Bladder Drug Average Price by Manufacturers (2019-2024)
2.4 Global Overactive Bladder Drug Industry Ranking 2022 VS 2023 VS 2024
2.5 Global Key Manufacturers of Overactive Bladder Drug, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Overactive Bladder Drug, Product Type & Application
2.7 Overactive Bladder Drug Market Competitive Situation and Trends
2.7.1 Overactive Bladder Drug Market Concentration Rate
2.7.2 The Global Top 5 and Top 10 Largest Overactive Bladder Drug Players Market Share by Revenue
2.7.3 Global Overactive Bladder Drug Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.8 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Overactive Bladder Drug Retrospective Market Scenario by Region
3.1 Global Overactive Bladder Drug Market Size by Region: 2019 Versus 2023 Versus 2030
3.2 Global Overactive Bladder Drug Global Overactive Bladder Drug Sales by Region: 2019-2030
3.2.1 Global Overactive Bladder Drug Sales by Region: 2019-2024
3.2.2 Global Overactive Bladder Drug Sales by Region: 2025-2030
3.3 Global Overactive Bladder Drug Global Overactive Bladder Drug Revenue by Region: 2019-2030
3.3.1 Global Overactive Bladder Drug Revenue by Region: 2019-2024
3.3.2 Global Overactive Bladder Drug Revenue by Region: 2025-2030
3.4 North America Overactive Bladder Drug Market Facts & Figures by Country
3.4.1 North America Overactive Bladder Drug Market Size by Country: 2019 VS 2023 VS 2030
3.4.2 North America Overactive Bladder Drug Sales by Country (2019-2030)
3.4.3 North America Overactive Bladder Drug Revenue by Country (2019-2030)
3.4.4 U.S.
3.4.5 Canada
3.5 Europe Overactive Bladder Drug Market Facts & Figures by Country
3.5.1 Europe Overactive Bladder Drug Market Size by Country: 2019 VS 2023 VS 2030
3.5.2 Europe Overactive Bladder Drug Sales by Country (2019-2030)
3.5.3 Europe Overactive Bladder Drug Revenue by Country (2019-2030)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Overactive Bladder Drug Market Facts & Figures by Country
3.6.1 Asia Pacific Overactive Bladder Drug Market Size by Country: 2019 VS 2023 VS 2030
3.6.2 Asia Pacific Overactive Bladder Drug Sales by Country (2019-2030)
3.6.3 Asia Pacific Overactive Bladder Drug Revenue by Country (2019-2030)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 Taiwan
3.6.10 Indonesia
3.6.11 Thailand
3.6.12 Malaysia
3.6.13 Philippines
3.7 Latin America Overactive Bladder Drug Market Facts & Figures by Country
3.7.1 Latin America Overactive Bladder Drug Market Size by Country: 2019 VS 2023 VS 2030
3.7.2 Latin America Overactive Bladder Drug Sales by Country (2019-2030)
3.7.3 Latin America Overactive Bladder Drug Revenue by Country (2019-2030)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa Overactive Bladder Drug Market Facts & Figures by Country
3.8.1 Middle East and Africa Overactive Bladder Drug Market Size by Country: 2019 VS 2023 VS 2030
3.8.2 Middle East and Africa Overactive Bladder Drug Sales by Country (2019-2030)
3.8.3 Middle East and Africa Overactive Bladder Drug Revenue by Country (2019-2030)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global Overactive Bladder Drug Sales by Type (2019-2030)
4.1.1 Global Overactive Bladder Drug Sales by Type (2019-2024)
4.1.2 Global Overactive Bladder Drug Sales by Type (2025-2030)
4.1.3 Global Overactive Bladder Drug Sales Market Share by Type (2019-2030)
4.2 Global Overactive Bladder Drug Revenue by Type (2019-2030)
4.2.1 Global Overactive Bladder Drug Revenue by Type (2019-2024)
4.2.2 Global Overactive Bladder Drug Revenue by Type (2025-2030)
4.2.3 Global Overactive Bladder Drug Revenue Market Share by Type (2019-2030)
4.3 Global Overactive Bladder Drug Price by Type (2019-2030)
5 Segment by Application
5.1 Global Overactive Bladder Drug Sales by Application (2019-2030)
5.1.1 Global Overactive Bladder Drug Sales by Application (2019-2024)
5.1.2 Global Overactive Bladder Drug Sales by Application (2025-2030)
5.1.3 Global Overactive Bladder Drug Sales Market Share by Application (2019-2030)
5.2 Global Overactive Bladder Drug Revenue by Application (2019-2030)
5.2.1 Global Overactive Bladder Drug Revenue by Application (2019-2024)
5.2.2 Global Overactive Bladder Drug Revenue by Application (2025-2030)
5.2.3 Global Overactive Bladder Drug Revenue Market Share by Application (2019-2030)
5.3 Global Overactive Bladder Drug Price by Application (2019-2030)
6 Key Companies Profiled
6.1 Astellas Pharma, Inc. (Japan)
6.1.1 Astellas Pharma, Inc. (Japan) Corporation Information
6.1.2 Astellas Pharma, Inc. (Japan) Description and Business Overview
6.1.3 Astellas Pharma, Inc. (Japan) Overactive Bladder Drug Sales, Revenue and Gross Margin (2019-2024)
6.1.4 Astellas Pharma, Inc. (Japan) Overactive Bladder Drug Product Portfolio
6.1.5 Astellas Pharma, Inc. (Japan) Recent Developments/Updates
6.2 Pfizer, Inc. (US)
6.2.1 Pfizer, Inc. (US) Corporation Information
6.2.2 Pfizer, Inc. (US) Description and Business Overview
6.2.3 Pfizer, Inc. (US) Overactive Bladder Drug Sales, Revenue and Gross Margin (2019-2024)
6.2.4 Pfizer, Inc. (US) Overactive Bladder Drug Product Portfolio
6.2.5 Pfizer, Inc. (US) Recent Developments/Updates
6.3 Teva Pharmaceutical Industries Limited (Israel)
6.3.1 Teva Pharmaceutical Industries Limited (Israel) Corporation Information
6.3.2 Teva Pharmaceutical Industries Limited (Israel) Description and Business Overview
6.3.3 Teva Pharmaceutical Industries Limited (Israel) Overactive Bladder Drug Sales, Revenue and Gross Margin (2019-2024)
6.3.4 Teva Pharmaceutical Industries Limited (Israel) Overactive Bladder Drug Product Portfolio
6.3.5 Teva Pharmaceutical Industries Limited (Israel) Recent Developments/Updates
6.4 Allergan, Plc (Ireland)
6.4.1 Allergan, Plc (Ireland) Corporation Information
6.4.2 Allergan, Plc (Ireland) Description and Business Overview
6.4.3 Allergan, Plc (Ireland) Overactive Bladder Drug Sales, Revenue and Gross Margin (2019-2024)
6.4.4 Allergan, Plc (Ireland) Overactive Bladder Drug Product Portfolio
6.4.5 Allergan, Plc (Ireland) Recent Developments/Updates
6.5 Medtronic plc (Ireland)
6.5.1 Medtronic plc (Ireland) Corporation Information
6.5.2 Medtronic plc (Ireland) Description and Business Overview
6.5.3 Medtronic plc (Ireland) Overactive Bladder Drug Sales, Revenue and Gross Margin (2019-2024)
6.5.4 Medtronic plc (Ireland) Overactive Bladder Drug Product Portfolio
6.5.5 Medtronic plc (Ireland) Recent Developments/Updates
6.6 Mylan N.V. (US)
6.6.1 Mylan N.V. (US) Corporation Information
6.6.2 Mylan N.V. (US) Description and Business Overview
6.6.3 Mylan N.V. (US) Overactive Bladder Drug Sales, Revenue and Gross Margin (2019-2024)
6.6.4 Mylan N.V. (US) Overactive Bladder Drug Product Portfolio
6.6.5 Mylan N.V. (US) Recent Developments/Updates
6.7 Endo International plc (Ireland)
6.6.1 Endo International plc (Ireland) Corporation Information
6.6.2 Endo International plc (Ireland) Description and Business Overview
6.6.3 Endo International plc (Ireland) Overactive Bladder Drug Sales, Revenue and Gross Margin (2019-2024)
6.4.4 Endo International plc (Ireland) Overactive Bladder Drug Product Portfolio
6.7.5 Endo International plc (Ireland) Recent Developments/Updates
6.8 Hisamitsu Pharmaceutical Co., Inc. (Japan)
6.8.1 Hisamitsu Pharmaceutical Co., Inc. (Japan) Corporation Information
6.8.2 Hisamitsu Pharmaceutical Co., Inc. (Japan) Description and Business Overview
6.8.3 Hisamitsu Pharmaceutical Co., Inc. (Japan) Overactive Bladder Drug Sales, Revenue and Gross Margin (2019-2024)
6.8.4 Hisamitsu Pharmaceutical Co., Inc. (Japan) Overactive Bladder Drug Product Portfolio
6.8.5 Hisamitsu Pharmaceutical Co., Inc. (Japan) Recent Developments/Updates
6.9 Sanofi (France)
6.9.1 Sanofi (France) Corporation Information
6.9.2 Sanofi (France) Description and Business Overview
6.9.3 Sanofi (France) Overactive Bladder Drug Sales, Revenue and Gross Margin (2019-2024)
6.9.4 Sanofi (France) Overactive Bladder Drug Product Portfolio
6.9.5 Sanofi (France) Recent Developments/Updates
6.10 Apotex, Inc. (Canada)
6.10.1 Apotex, Inc. (Canada) Corporation Information
6.10.2 Apotex, Inc. (Canada) Description and Business Overview
6.10.3 Apotex, Inc. (Canada) Overactive Bladder Drug Sales, Revenue and Gross Margin (2019-2024)
6.10.4 Apotex, Inc. (Canada) Overactive Bladder Drug Product Portfolio
6.10.5 Apotex, Inc. (Canada) Recent Developments/Updates
6.11 Cogentix Medical, Inc. (US)
6.11.1 Cogentix Medical, Inc. (US) Corporation Information
6.11.2 Cogentix Medical, Inc. (US) Overactive Bladder Drug Description and Business Overview
6.11.3 Cogentix Medical, Inc. (US) Overactive Bladder Drug Sales, Revenue and Gross Margin (2019-2024)
6.11.4 Cogentix Medical, Inc. (US) Overactive Bladder Drug Product Portfolio
6.11.5 Cogentix Medical, Inc. (US) Recent Developments/Updates
6.12 Aurobindo Pharma Limited (India)
6.12.1 Aurobindo Pharma Limited (India) Corporation Information
6.12.2 Aurobindo Pharma Limited (India) Overactive Bladder Drug Description and Business Overview
6.12.3 Aurobindo Pharma Limited (India) Overactive Bladder Drug Sales, Revenue and Gross Margin (2019-2024)
6.12.4 Aurobindo Pharma Limited (India) Overactive Bladder Drug Product Portfolio
6.12.5 Aurobindo Pharma Limited (India) Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Overactive Bladder Drug Industry Chain Analysis
7.2 Overactive Bladder Drug Key Raw Materials
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Overactive Bladder Drug Production Mode & Process
7.4 Overactive Bladder Drug Sales and Marketing
7.4.1 Overactive Bladder Drug Sales Channels
7.4.2 Overactive Bladder Drug Distributors
7.5 Overactive Bladder Drug Customers
8 Overactive Bladder Drug Market Dynamics
8.1 Overactive Bladder Drug Industry Trends
8.2 Overactive Bladder Drug Market Drivers
8.3 Overactive Bladder Drug Market Challenges
8.4 Overactive Bladder Drug Market Restraints
9 Research Finding and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
List of TablesList of Tables
Table 1. Global Overactive Bladder Drug Market Value Comparison by Type (2024-2030) & (US$ Million)
Table 2. Global Overactive Bladder Drug Market Value Comparison by Application (2024-2030) & (US$ Million)
Table 3. Global Overactive Bladder Drug Market Competitive Situation by Manufacturers in 2023
Table 4. Global Overactive Bladder Drug Sales (K Units) of Key Manufacturers (2019-2024)
Table 5. Global Overactive Bladder Drug Sales Market Share by Manufacturers (2019-2024)
Table 6. Global Overactive Bladder Drug Revenue (US$ Million) by Manufacturers (2019-2024)
Table 7. Global Overactive Bladder Drug Revenue Share by Manufacturers (2019-2024)
Table 8. Global Market Overactive Bladder Drug Average Price (USD/Unit) of Key Manufacturers (2019-2024)
Table 9. Global Key Players of Overactive Bladder Drug, Industry Ranking, 2022 VS 2023 VS 2024
Table 10. Global Key Manufacturers of Overactive Bladder Drug, Manufacturing Sites & Headquarters
Table 11. Global Key Manufacturers of Overactive Bladder Drug, Product Type & Application
Table 12. Global Key Manufacturers of Overactive Bladder Drug, Date of Enter into This Industry
Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 14. Global Overactive Bladder Drug by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Overactive Bladder Drug as of 2023)
Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 16. Global Overactive Bladder Drug Market Size by Region (US$ Million): 2019 VS 2023 VS 2030
Table 17. Global Overactive Bladder Drug Sales by Region (2019-2024) & (K Units)
Table 18. Global Overactive Bladder Drug Sales Market Share by Region (2019-2024)
Table 19. Global Overactive Bladder Drug Sales by Region (2025-2030) & (K Units)
Table 20. Global Overactive Bladder Drug Sales Market Share by Region (2025-2030)
Table 21. Global Overactive Bladder Drug Revenue by Region (2019-2024) & (US$ Million)
Table 22. Global Overactive Bladder Drug Revenue Market Share by Region (2019-2024)
Table 23. Global Overactive Bladder Drug Revenue by Region (2025-2030) & (US$ Million)
Table 24. Global Overactive Bladder Drug Revenue Market Share by Region (2025-2030)
Table 25. North America Overactive Bladder Drug Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)
Table 26. North America Overactive Bladder Drug Sales by Country (2019-2024) & (K Units)
Table 27. North America Overactive Bladder Drug Sales by Country (2025-2030) & (K Units)
Table 28. North America Overactive Bladder Drug Revenue by Country (2019-2024) & (US$ Million)
Table 29. North America Overactive Bladder Drug Revenue by Country (2025-2030) & (US$ Million)
Table 30. Europe Overactive Bladder Drug Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)
Table 31. Europe Overactive Bladder Drug Sales by Country (2019-2024) & (K Units)
Table 32. Europe Overactive Bladder Drug Sales by Country (2025-2030) & (K Units)
Table 33. Europe Overactive Bladder Drug Revenue by Country (2019-2024) & (US$ Million)
Table 34. Europe Overactive Bladder Drug Revenue by Country (2025-2030) & (US$ Million)
Table 35. Asia Pacific Overactive Bladder Drug Revenue by Region: 2019 VS 2023 VS 2030 (US$ Million)
Table 36. Asia Pacific Overactive Bladder Drug Sales by Region (2019-2024) & (K Units)
Table 37. Asia Pacific Overactive Bladder Drug Sales by Region (2025-2030) & (K Units)
Table 38. Asia Pacific Overactive Bladder Drug Revenue by Region (2019-2024) & (US$ Million)
Table 39. Asia Pacific Overactive Bladder Drug Revenue by Region (2025-2030) & (US$ Million)
Table 40. Latin America Overactive Bladder Drug Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)
Table 41. Latin America Overactive Bladder Drug Sales by Country (2019-2024) & (K Units)
Table 42. Latin America Overactive Bladder Drug Sales by Country (2025-2030) & (K Units)
Table 43. Latin America Overactive Bladder Drug Revenue by Country (2019-2024) & (US$ Million)
Table 44. Latin America Overactive Bladder Drug Revenue by Country (2025-2030) & (US$ Million)
Table 45. Middle East & Africa Overactive Bladder Drug Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)
Table 46. Middle East & Africa Overactive Bladder Drug Sales by Country (2019-2024) & (K Units)
Table 47. Middle East & Africa Overactive Bladder Drug Sales by Country (2025-2030) & (K Units)
Table 48. Middle East & Africa Overactive Bladder Drug Revenue by Country (2019-2024) & (US$ Million)
Table 49. Middle East & Africa Overactive Bladder Drug Revenue by Country (2025-2030) & (US$ Million)
Table 50. Global Overactive Bladder Drug Sales (K Units) by Type (2019-2024)
Table 51. Global Overactive Bladder Drug Sales (K Units) by Type (2025-2030)
Table 52. Global Overactive Bladder Drug Sales Market Share by Type (2019-2024)
Table 53. Global Overactive Bladder Drug Sales Market Share by Type (2025-2030)
Table 54. Global Overactive Bladder Drug Revenue (US$ Million) by Type (2019-2024)
Table 55. Global Overactive Bladder Drug Revenue (US$ Million) by Type (2025-2030)
Table 56. Global Overactive Bladder Drug Revenue Market Share by Type (2019-2024)
Table 57. Global Overactive Bladder Drug Revenue Market Share by Type (2025-2030)
Table 58. Global Overactive Bladder Drug Price (USD/Unit) by Type (2019-2024)
Table 59. Global Overactive Bladder Drug Price (USD/Unit) by Type (2025-2030)
Table 60. Global Overactive Bladder Drug Sales (K Units) by Application (2019-2024)
Table 61. Global Overactive Bladder Drug Sales (K Units) by Application (2025-2030)
Table 62. Global Overactive Bladder Drug Sales Market Share by Application (2019-2024)
Table 63. Global Overactive Bladder Drug Sales Market Share by Application (2025-2030)
Table 64. Global Overactive Bladder Drug Revenue (US$ Million) by Application (2019-2024)
Table 65. Global Overactive Bladder Drug Revenue (US$ Million) by Application (2025-2030)
Table 66. Global Overactive Bladder Drug Revenue Market Share by Application (2019-2024)
Table 67. Global Overactive Bladder Drug Revenue Market Share by Application (2025-2030)
Table 68. Global Overactive Bladder Drug Price (USD/Unit) by Application (2019-2024)
Table 69. Global Overactive Bladder Drug Price (USD/Unit) by Application (2025-2030)
Table 70. Astellas Pharma, Inc. (Japan) Corporation Information
Table 71. Astellas Pharma, Inc. (Japan) Description and Business Overview
Table 72. Astellas Pharma, Inc. (Japan) Overactive Bladder Drug Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
Table 73. Astellas Pharma, Inc. (Japan) Overactive Bladder Drug Product
Table 74. Astellas Pharma, Inc. (Japan) Recent Developments/Updates
Table 75. Pfizer, Inc. (US) Corporation Information
Table 76. Pfizer, Inc. (US) Description and Business Overview
Table 77. Pfizer, Inc. (US) Overactive Bladder Drug Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
Table 78. Pfizer, Inc. (US) Overactive Bladder Drug Product
Table 79. Pfizer, Inc. (US) Recent Developments/Updates
Table 80. Teva Pharmaceutical Industries Limited (Israel) Corporation Information
Table 81. Teva Pharmaceutical Industries Limited (Israel) Description and Business Overview
Table 82. Teva Pharmaceutical Industries Limited (Israel) Overactive Bladder Drug Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
Table 83. Teva Pharmaceutical Industries Limited (Israel) Overactive Bladder Drug Product
Table 84. Teva Pharmaceutical Industries Limited (Israel) Recent Developments/Updates
Table 85. Allergan, Plc (Ireland) Corporation Information
Table 86. Allergan, Plc (Ireland) Description and Business Overview
Table 87. Allergan, Plc (Ireland) Overactive Bladder Drug Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
Table 88. Allergan, Plc (Ireland) Overactive Bladder Drug Product
Table 89. Allergan, Plc (Ireland) Recent Developments/Updates
Table 90. Medtronic plc (Ireland) Corporation Information
Table 91. Medtronic plc (Ireland) Description and Business Overview
Table 92. Medtronic plc (Ireland) Overactive Bladder Drug Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
Table 93. Medtronic plc (Ireland) Overactive Bladder Drug Product
Table 94. Medtronic plc (Ireland) Recent Developments/Updates
Table 95. Mylan N.V. (US) Corporation Information
Table 96. Mylan N.V. (US) Description and Business Overview
Table 97. Mylan N.V. (US) Overactive Bladder Drug Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
Table 98. Mylan N.V. (US) Overactive Bladder Drug Product
Table 99. Mylan N.V. (US) Recent Developments/Updates
Table 100. Endo International plc (Ireland) Corporation Information
Table 101. Endo International plc (Ireland) Description and Business Overview
Table 102. Endo International plc (Ireland) Overactive Bladder Drug Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
Table 103. Endo International plc (Ireland) Overactive Bladder Drug Product
Table 104. Endo International plc (Ireland) Recent Developments/Updates
Table 105. Hisamitsu Pharmaceutical Co., Inc. (Japan) Corporation Information
Table 106. Hisamitsu Pharmaceutical Co., Inc. (Japan) Description and Business Overview
Table 107. Hisamitsu Pharmaceutical Co., Inc. (Japan) Overactive Bladder Drug Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
Table 108. Hisamitsu Pharmaceutical Co., Inc. (Japan) Overactive Bladder Drug Product
Table 109. Hisamitsu Pharmaceutical Co., Inc. (Japan) Recent Developments/Updates
Table 110. Sanofi (France) Corporation Information
Table 111. Sanofi (France) Description and Business Overview
Table 112. Sanofi (France) Overactive Bladder Drug Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
Table 113. Sanofi (France) Overactive Bladder Drug Product
Table 114. Sanofi (France) Recent Developments/Updates
Table 115. Apotex, Inc. (Canada) Corporation Information
Table 116. Apotex, Inc. (Canada) Description and Business Overview
Table 117. Apotex, Inc. (Canada) Overactive Bladder Drug Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
Table 118. Apotex, Inc. (Canada) Overactive Bladder Drug Product
Table 119. Apotex, Inc. (Canada) Recent Developments/Updates
Table 120. Cogentix Medical, Inc. (US) Corporation Information
Table 121. Cogentix Medical, Inc. (US) Description and Business Overview
Table 122. Cogentix Medical, Inc. (US) Overactive Bladder Drug Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
Table 123. Cogentix Medical, Inc. (US) Overactive Bladder Drug Product
Table 124. Cogentix Medical, Inc. (US) Recent Developments/Updates
Table 125. Aurobindo Pharma Limited (India) Corporation Information
Table 126. Aurobindo Pharma Limited (India) Description and Business Overview
Table 127. Aurobindo Pharma Limited (India) Overactive Bladder Drug Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
Table 128. Aurobindo Pharma Limited (India) Overactive Bladder Drug Product
Table 129. Aurobindo Pharma Limited (India) Recent Developments/Updates
Table 130. Key Raw Materials Lists
Table 131. Raw Materials Key Suppliers Lists
Table 132. Overactive Bladder Drug Distributors List
Table 133. Overactive Bladder Drug Customers List
Table 134. Overactive Bladder Drug Market Trends
Table 135. Overactive Bladder Drug Market Drivers
Table 136. Overactive Bladder Drug Market Challenges
Table 137. Overactive Bladder Drug Market Restraints
Table 138. Research Programs/Design for This Report
Table 139. Key Data Information from Secondary Sources
Table 140. Key Data Information from Primary Sources
List of Figures
Figure 1. Product Picture of Overactive Bladder Drug
Figure 2. Global Overactive Bladder Drug Market Value Comparison by Type (2024-2030) & (US$ Million)
Figure 3. Global Overactive Bladder Drug Market Share by Type in 2023 & 2030
Figure 4. Anticholinergics Product Picture
Figure 5. Solifenacin Product Picture
Figure 6. Oxybutynin Product Picture
Figure 7. Darifenacin Product Picture
Figure 8. Fesoterodine Product Picture
Figure 9. Tolterodine Product Picture
Figure 10. Trospium Product Picture
Figure 11. Others Product Picture
Figure 12. Global Overactive Bladder Drug Market Value Comparison by Application (2024-2030) & (US$ Million)
Figure 13. Global Overactive Bladder Drug Market Share by Application in 2023 & 2030
Figure 14. Idiopathic Bladder Overactivity
Figure 15. Neurogenic Bladder Overactivity
Figure 16. Global Overactive Bladder Drug Revenue, (US$ Million), 2019 VS 2023 VS 2030
Figure 17. Global Overactive Bladder Drug Market Size (2019-2030) & (US$ Million)
Figure 18. Global Overactive Bladder Drug Sales (2019-2030) & (K Units)
Figure 19. Global Overactive Bladder Drug Average Price (USD/Unit) & (2019-2030)
Figure 20. Overactive Bladder Drug Report Years Considered
Figure 21. Overactive Bladder Drug Sales Share by Manufacturers in 2023
Figure 22. Global Overactive Bladder Drug Revenue Share by Manufacturers in 2023
Figure 23. The Global 5 and 10 Largest Overactive Bladder Drug Players: Market Share by Revenue in 2023
Figure 24. Overactive Bladder Drug Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2019 VS 2023
Figure 25. Global Overactive Bladder Drug Market Size by Region (US$ Million): 2019 VS 2023 VS 2030
Figure 26. North America Overactive Bladder Drug Sales Market Share by Country (2019-2030)
Figure 27. North America Overactive Bladder Drug Revenue Market Share by Country (2019-2030)
Figure 28. U.S. Overactive Bladder Drug Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 29. Canada Overactive Bladder Drug Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 30. Europe Overactive Bladder Drug Sales Market Share by Country (2019-2030)
Figure 31. Europe Overactive Bladder Drug Revenue Market Share by Country (2019-2030)
Figure 32. Germany Overactive Bladder Drug Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 33. France Overactive Bladder Drug Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 34. U.K. Overactive Bladder Drug Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 35. Italy Overactive Bladder Drug Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 36. Russia Overactive Bladder Drug Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 37. Asia Pacific Overactive Bladder Drug Sales Market Share by Region (2019-2030)
Figure 38. Asia Pacific Overactive Bladder Drug Revenue Market Share by Region (2019-2030)
Figure 39. China Overactive Bladder Drug Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 40. Japan Overactive Bladder Drug Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 41. South Korea Overactive Bladder Drug Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 42. India Overactive Bladder Drug Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 43. Australia Overactive Bladder Drug Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 44. Taiwan Overactive Bladder Drug Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 45. Indonesia Overactive Bladder Drug Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 46. Thailand Overactive Bladder Drug Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 47. Malaysia Overactive Bladder Drug Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 48. Philippines Overactive Bladder Drug Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 49. Latin America Overactive Bladder Drug Sales Market Share by Country (2019-2030)
Figure 50. Latin America Overactive Bladder Drug Revenue Market Share by Country (2019-2030)
Figure 51. Mexico Overactive Bladder Drug Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 52. Brazil Overactive Bladder Drug Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 53. Argentina Overactive Bladder Drug Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 54. Middle East & Africa Overactive Bladder Drug Sales Market Share by Country (2019-2030)
Figure 55. Middle East & Africa Overactive Bladder Drug Revenue Market Share by Country (2019-2030)
Figure 56. Turkey Overactive Bladder Drug Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 57. Saudi Arabia Overactive Bladder Drug Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 58. UAE Overactive Bladder Drug Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 59. Global Sales Market Share of Overactive Bladder Drug by Type (2019-2030)
Figure 60. Global Revenue Market Share of Overactive Bladder Drug by Type (2019-2030)
Figure 61. Global Overactive Bladder Drug Price (USD/Unit) by Type (2019-2030)
Figure 62. Global Sales Market Share of Overactive Bladder Drug by Application (2019-2030)
Figure 63. Global Revenue Market Share of Overactive Bladder Drug by Application (2019-2030)
Figure 64. Global Overactive Bladder Drug Price (USD/Unit) by Application (2019-2030)
Figure 65. Overactive Bladder Drug Value Chain
Figure 66. Overactive Bladder Drug Production Process
Figure 67. Channels of Distribution (Direct Vs Distribution)
Figure 68. Distributors Profiles
Figure 69. Bottom-up and Top-down Approaches for This Report
Figure 70. Data Triangulation
Figure 71. Key Executives Interviewed
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
